{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:05:47Z","timestamp":1768824347766,"version":"3.49.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a potentially severe respiratory disease, the coronavirus disease 2019 (COVID-19), an ongoing pandemic with limited therapeutic options. Here, we assessed the anti-coronavirus activity of synthetic RNAs mimicking specific domains in the non-coding regions of the foot-and-mouth disease virus (FMDV) genome (ncRNAs). These molecules are known to exert broad-spectrum antiviral activity in cell culture, mice and pigs effectively triggering the host innate immune response. The ncRNAs showed potent antiviral activity against SARS-CoV-2 after transfection in human intestinal Caco-2 and lung epithelium Calu-3 2B4 cells. When the <jats:italic>in vivo<\/jats:italic> efficacy of the FMDV ncRNAs was assessed in K18-hACE2 mice, administration of naked ncRNA before intranasal SARS-CoV-2 infection significantly decreased the viral load and the levels of pro-inflammatory cytokines in the lungs compared with untreated infected mice. The ncRNAs were also highly efficacious when assayed against common human HCoV-229E and porcine transmissible gastroenteritis virus (TGEV) in hepatocyte-derived Huh-7 and swine testis ST cells, respectively. These results are a proof of concept of the pan-coronavirus antiviral activity of the FMDV ncRNAs including human and animal divergent coronaviruses and potentially enhance our ability to fight future emerging variants.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1166725","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T07:21:22Z","timestamp":1680074482000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Non-coding RNAs derived from the foot-and-mouth disease virus genome trigger broad antiviral activity against coronaviruses"],"prefix":"10.3389","volume":"14","author":[{"given":"Miguel","family":"Rodr\u00edguez-Pulido","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Calvo-Pinilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miryam","family":"Polo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan-Carlos","family":"Saiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal","family":"Fern\u00e1ndez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Pericuesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Guti\u00e9rrez-Ad\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Sobrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Mart\u00edn-Acebes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"S\u00e1iz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030524","article-title":"Post-COVID-19 syndrome: Involvement and interactions between respiratory, cardiovascular and nervous systems","volume":"11","author":"Visco","year":"2022","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 m(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat Microbiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for covid-19 - interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"N Engl J Med"},{"key":"B9","first-page":"19","article-title":"Genome organisation, translation and replication of FMDV RNA","volume-title":"Foot-and-mouth disease: Current perspectives","author":"Belsham","year":"2004"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00599-11","article-title":"RNA Structural domains in non-coding regions of foot-and-mouth disease virus genome trigger innate immunity in porcine cells and mice","volume":"85","author":"Rodriguez-Pulido","year":"2011","journal-title":"J Virol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/v7072807","article-title":"Synthetic RNAs mimicking structural domains in the foot-and-Mouth disease virus genome elicit a broad innate immune response in porcine cells triggered by RIG-I and TLR activation","volume":"7","author":"Borrego","year":"2015","journal-title":"Viruses."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.10.005","article-title":"Inoculation of newborn mice with non-coding regions of foot-and-mouth disease virus RNA can induce a rapid, solid and wide-range protection against viral infection","volume":"92","author":"Rodriguez-Pulido","year":"2011","journal-title":"Antiviral Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049494","article-title":"Protection against West Nile virus infection in mice after inoculation with type I interferon-inducing RNA transcripts","volume":"7","author":"Rodriguez-Pulido","year":"2012","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.06.010","article-title":"Protection against rift valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome","volume":"109","author":"Lorenzo","year":"2014","journal-title":"Antiviral Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2020.00495","article-title":"A wide-ranging antiviral response in wild boar cells is triggered by non-coding synthetic RNAs from the foot-and-Mouth disease virus genome","volume":"7","author":"Rodriguez Pulido","year":"2020","journal-title":"Front Vet Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.03.009","article-title":"Combined administration of synthetic RNA and a conventional vaccine improves immune responses and protection against foot-and-mouth disease virus in swine","volume":"142","author":"Borrego","year":"2017","journal-title":"Antiviral Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008729","article-title":"Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection","volume":"5","author":"Yoshikawa","year":"2010","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.863831","article-title":"Nanobodies protecting from lethal SARS-CoV-2 infection target receptor binding epitopes preserved in virus variants other than omicron","volume":"13","author":"Casasnovas","year":"2022","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020","article-title":"A mouse model of SARS-CoV-2 infection and pathogenesis","volume":"28","author":"Sun","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2019.1604084","article-title":"Targeting host metabolism by inhibition of acetyl-coenzyme a carboxylase reduces flavivirus infection in mouse models","volume":"8","author":"Jimenez de Oya","year":"2019","journal-title":"Emerg Microbes Infect"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02012-06","article-title":"Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus","volume":"81","author":"McCray","year":"2007","journal-title":"J Virol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00211-22","article-title":"Angiotensin-converting enzyme 2 potentiates SARS-CoV-2 infection by antagonizing type I interferon induction and its down-stream signaling pathway","volume":"7","author":"Chen","year":"2022","journal-title":"mSphere."},{"key":"B23","doi-asserted-by":"publisher","first-page":"198925","DOI":"10.1016\/j.virusres.2022.198925","article-title":"More tools for our toolkit: The application of HEL-299 cells and dsRNA-nanoparticles to study human coronaviruses in vitro","volume":"321","author":"Semple","year":"2022","journal-title":"Virus Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0022-1759(01)00570-1","article-title":"Biological assays for interferons","volume":"261","author":"Meager","year":"2002","journal-title":"J Immunol Methods"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02415-20","article-title":"SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells","volume":"95","author":"Rebendenne","year":"2021","journal-title":"J Virol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"108628","DOI":"10.1016\/j.celrep.2020.108628","article-title":"MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells","volume":"34","author":"Yin","year":"2021","journal-title":"Cell Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12985-018-1012-9","article-title":"Impact of TGEV infection on the pig small intestine","volume":"15","author":"Xia","year":"2018","journal-title":"Virol J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"107931","DOI":"10.1016\/j.pharmthera.2021.107931","article-title":"Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions","volume":"228","author":"Renn","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1038\/s41467-020-19891-7","article-title":"Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice","volume":"11","author":"Oladunni","year":"2020","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0778-2","article-title":"SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function","volume":"21","author":"Winkler","year":"2020","journal-title":"Nat Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01091-0","article-title":"Innate immunity: the first line of defense against SARS-CoV-2","volume":"23","author":"Diamond","year":"2022","journal-title":"Nat Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/v14061247","article-title":"Characterization of SARS-CoV-2 evasion: Interferon pathway and therapeutic options","volume":"14","author":"Znaidia","year":"2022","journal-title":"Viruses."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940756","article-title":"Roles and functions of SARS-CoV-2 proteins in host immune evasion","volume":"13","author":"Rashid","year":"2022","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.02.014","article-title":"The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies","volume":"30","author":"Zhang","year":"2022","journal-title":"Mol Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/v14030530","article-title":"Escape and over-activation of innate immune responses by SARS-CoV-2: Two faces of a coin","volume":"14","author":"Mattoo","year":"2022","journal-title":"Viruses."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell."},{"key":"B37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/imr.13113","article-title":"Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection","volume":"309","author":"Chiale","year":"2022","journal-title":"Immunol Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.05.004","article-title":"Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19","volume":"29","author":"Lowery","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B39","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.chom.2020.07.005","article-title":"Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients","volume":"28","author":"Wang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.03.015","article-title":"Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study","volume":"105","author":"Pandit","year":"2021","journal-title":"Int J Infect Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.21203\/rs.3.rs-136499\/v1","article-title":"Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial","volume":"11","author":"Alavi Darazam","year":"2021","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S2213-2600(20)30566-X","article-title":"Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial","volume":"9","author":"Feld","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.immuni.2021.01.017","article-title":"Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity","volume":"54","author":"Hoagland","year":"2021","journal-title":"Immunity."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/v14020189","article-title":"Induction of innate immune response by TLR3 agonist protects mice against SARS-CoV-2 infection","volume":"14","author":"Tamir","year":"2022","journal-title":"Viruses"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20211818","article-title":"A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice","volume":"219","author":"Mao","year":"2022","journal-title":"J Exp Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2022.02.008","article-title":"RIG-i-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection","volume":"27","author":"Marx","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi9002","article-title":"A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection","volume":"6","author":"Humphries","year":"2021","journal-title":"Sci Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi9007","article-title":"Pharmacological activation of STING blocks SARS-CoV-2 infection","volume":"6","author":"Li","year":"2021","journal-title":"Sci Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1166725\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T07:21:25Z","timestamp":1680074485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1166725\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2023.1166725"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1166725","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"article-number":"1166725"}}